Maurizio Grassano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maurizio Grassano has a total of 307 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Canosa
Rita Levi Montalcini Department of Neuroscience University of Turin Turin Italy
24 shared publications - Andrea Calvo
‘Rita Levi Montalcini’ Department of Neuroscience University of Torino Torino Italy
22 shared publications - Adriano Chiò
‘Rita Levi Montalcini’ Department of Neuroscience University of Torino Torino Italy
21 shared publications - Rosario Vasta
ALS Center, Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy
20 shared publications - Cristina Moglia
ALS Center, ‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, Italy
16 shared publications - Umberto Manera
University of Turin
15 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , 682-693.e5
Advance Care Planning in Amyotrophic Lateral Sclerosis: A Retrospective Population-based Study
- 12 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , 682-693.e5
Open AccessAdvance Care Planning in Amyotrophic Lateral Sclerosis: A Retrospective Population-based Study
- Open Access
- 10 February 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1536-1544
Sex‐Specific Genetic Architecture of ALS : Evidence of a Female Protective Effect?
Background: Amyotrophic lateral sclerosis (ALS) shows sex differences in incidence and age of onset, yet the underlying biological mechanisms remain poorly understood. Methods: We investigated sex‐specific genetic architecture in an Italian ALS cohort with whole‐genome sequencing (1,333 ALS cases, 755 controls). We performed a sex‐stratified burden analysis of rare variants in ALS‐associated genes and compared the proportions of male and female ALS patients carrying pathogenic or rare damaging variants. Key findings were replicated in the AnswerALS cohort ( n = 723). Gene‐specific sex ratios and familial history for C9ORF72 , SOD1 , and TARDBP were examined in an expanded dataset of 2,301 Italian ALS patients. Results: Sex‐stratified burden testing revealed that rare variants in ALS genes were enriched in female cases versus controls (odds ratio [OR] 5.47, 95% confidence interval [CI] 1.60–34.29) but not in male cases. Female ALS patients more frequently carried rare damaging variants compared to males (23.2% vs 18.3%; OR 1.38, 95% CI 1.05–1.81), a finding that was replicated in the AnswerALS cohort (18.9% vs 12.4%; OR 1.58, 95% CI 1.10–2.26). Gene‐level analyses of TARDBP carriers revealed a male predominance (2.1:1), yet a higher rate of familial history among females (40.4% vs 24.5%; OR 2.13, 95% CI 1.03–4.39). Interpretation: Females with ALS exhibited a higher overall burden of rare damaging variants, suggesting sex‐related differences in genetic liability. Gene‐level analyses indicate that the influence of sex varies across ALS genes, particularly TARDBP . These findings help explain epidemiological patterns and have implications for the identification of sex‐linked protective mechanisms. ANN NEUROL 2026;99:1536–1544
- 10 February 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1536-1544
Open AccessSex‐Specific Genetic Architecture of ALS : Evidence of a Female Protective Effect?
Background: Amyotrophic lateral sclerosis (ALS) shows sex differences in incidence and age of onset, yet the underlying biological mechanisms remain poorly understood. Methods: We investigated sex‐specific genetic architecture in an Italian ALS cohort with whole‐genome sequencing (1,333 ALS cases, 755 controls). We performed a sex‐stratified burden analysis of rare variants in ALS‐associated genes and compared the proportions of male and female ALS patients carrying pathogenic or rare damaging variants. Key findings were replicated in the AnswerALS cohort ( n = 723). Gene‐specific sex ratios and familial history for C9ORF72 , SOD1 , and TARDBP were examined in an expanded dataset of 2,301 Italian ALS patients. Results: Sex‐stratified burden testing revealed that rare variants in ALS genes were enriched in female cases versus controls (odds ratio [OR] 5.47, 95% confidence interval [CI] 1.60–34.29) but not in male cases. Female ALS patients more frequently carried rare damaging variants compared to males (23.2% vs 18.3%; OR 1.38, 95% CI 1.05–1.81), a finding that was replicated in the AnswerALS cohort (18.9% vs 12.4%; OR 1.58, 95% CI 1.10–2.26). Gene‐level analyses of TARDBP carriers revealed a male predominance (2.1:1), yet a higher rate of familial history among females (40.4% vs 24.5%; OR 2.13, 95% CI 1.03–4.39). Interpretation: Females with ALS exhibited a higher overall burden of rare damaging variants, suggesting sex‐related differences in genetic liability. Gene‐level analyses indicate that the influence of sex varies across ALS genes, particularly TARDBP . These findings help explain epidemiological patterns and have implications for the identification of sex‐linked protective mechanisms. ANN NEUROL 2026;99:1536–1544
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214180
Genetic Variants Associated With Neurodegenerative Disorders in Patients With Amyotrophic Lateral Sclerosis and Phenotypic Variability
The genetic contribution to clinical heterogeneity in amyotrophic lateral sclerosis (ALS) remains poorly understood, particularly regarding the role of genes associated with other neurodegenerative disorders. This study aimed to determine whether rare variants in neurodegeneration-associated genes influence ALS risk and clinical phenotype. This case-control study included patients with ALS without pathogenic variants in major ALS genes from the population-based Piemonte and Valle d'Aosta Register for ALS and matched controls. High-impact rare variants (minor allele frequency p = 0.027). In particular, novel variants in Parkinson disease-associated genes (OR 3.62; 95% CI 1.33-9.80; p = 0.01) and hereditary neuropathy genes (OR 3.30; 95% CI 1.55-7.03; p = 0.002) conferred a 3-fold increased risk. These findings were independently replicated in the Project MinE dataset (OR 1.43; 95% CI 1.30-1.57; p < 0.001). Stratified analysis also confirmed the enrichment of rare variants in Parkinson disease and hereditary neuropathy-associated genes. Variant carriers were more likely to present with the flail arm phenotype (OR 2.05; 95% CI 1.05-3.98; p = 0.03) and showed increased risk of frontotemporal dementia (OR 1.85; 95% CI 1.04-3.21; p = 0.03) and shorter survival (hazard ratio 1.99; 95% CI 1.26-3.14; p = 0.003). Rare variants in genes associated with other neurodegenerative disorders influence both ALS susceptibility and clinical features, highlighting genetic pleiotropy across neurodegenerative diseases. Our findings support a model in which ALS arises from a complex and heterogeneous genetic landscape involving multiple variants, often shared with other neurodegenerative conditions, that shape disease expression. Although these findings suggest potential future expansion of genetic screening beyond classical ALS genes, such variants should be interpreted cautiously in clinical practice pending further functional validation.
- 21 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214180
Open AccessGenetic Variants Associated With Neurodegenerative Disorders in Patients With Amyotrophic Lateral Sclerosis and Phenotypic Variability
The genetic contribution to clinical heterogeneity in amyotrophic lateral sclerosis (ALS) remains poorly understood, particularly regarding the role of genes associated with other neurodegenerative disorders. This study aimed to determine whether rare variants in neurodegeneration-associated genes influence ALS risk and clinical phenotype. This case-control study included patients with ALS without pathogenic variants in major ALS genes from the population-based Piemonte and Valle d'Aosta Register for ALS and matched controls. High-impact rare variants (minor allele frequency p = 0.027). In particular, novel variants in Parkinson disease-associated genes (OR 3.62; 95% CI 1.33-9.80; p = 0.01) and hereditary neuropathy genes (OR 3.30; 95% CI 1.55-7.03; p = 0.002) conferred a 3-fold increased risk. These findings were independently replicated in the Project MinE dataset (OR 1.43; 95% CI 1.30-1.57; p < 0.001). Stratified analysis also confirmed the enrichment of rare variants in Parkinson disease and hereditary neuropathy-associated genes. Variant carriers were more likely to present with the flail arm phenotype (OR 2.05; 95% CI 1.05-3.98; p = 0.03) and showed increased risk of frontotemporal dementia (OR 1.85; 95% CI 1.04-3.21; p = 0.03) and shorter survival (hazard ratio 1.99; 95% CI 1.26-3.14; p = 0.003). Rare variants in genes associated with other neurodegenerative disorders influence both ALS susceptibility and clinical features, highlighting genetic pleiotropy across neurodegenerative diseases. Our findings support a model in which ALS arises from a complex and heterogeneous genetic landscape involving multiple variants, often shared with other neurodegenerative conditions, that shape disease expression. Although these findings suggest potential future expansion of genetic screening beyond classical ALS genes, such variants should be interpreted cautiously in clinical practice pending further functional validation.
- Top Cited PapersOpen Access
- 19 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3440-3450
A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis
Identifying a reliable biomarker for amyotrophic lateral sclerosis (ALS) is crucial for clinical practice. Here, in this cross-sectional study, we used the Olink Explore 3072 platform to investigate plasma proteomics as a biomarker tool for this neurodegenerative condition. Thirty-three proteins were differentially abundant in the plasma of patients with ALS (n = 183) versus controls (n = 309). We replicated our findings in an independent cohort (n = 48 patients with ALS and n = 75 controls). We then applied machine learning to create a model that diagnosed ALS with high accuracy (area under the curve, 98.3%). By analyzing plasma samples from individuals before ALS symptoms emerged, we estimated the age of clinical onset and showed that the disease process—impacting skeletal muscle, nerves and energy metabolism—occurs years before symptoms appear. Our research suggests that plasma proteins can be a biomarker for this fatal disease and offers molecular insights into its prodromal phase.
- 19 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3440-3450
Top Cited PapersOpen AccessA plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis
Identifying a reliable biomarker for amyotrophic lateral sclerosis (ALS) is crucial for clinical practice. Here, in this cross-sectional study, we used the Olink Explore 3072 platform to investigate plasma proteomics as a biomarker tool for this neurodegenerative condition. Thirty-three proteins were differentially abundant in the plasma of patients with ALS (n = 183) versus controls (n = 309). We replicated our findings in an independent cohort (n = 48 patients with ALS and n = 75 controls). We then applied machine learning to create a model that diagnosed ALS with high accuracy (area under the curve, 98.3%). By analyzing plasma samples from individuals before ALS symptoms emerged, we estimated the age of clinical onset and showed that the disease process—impacting skeletal muscle, nerves and energy metabolism—occurs years before symptoms appear. Our research suggests that plasma proteins can be a biomarker for this fatal disease and offers molecular insights into its prodromal phase.
- Open Access
- 22 April 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (8) , e213467
Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995–2018)
The average survival of patients with amyotrophic lateral sclerosis (ALS) ranges from 2 to 5 years from symptom onset. However, it remains unclear whether this estimate has improved over time. The objective of this study was to analyze the survival trend of a large population-based cohort of patients with ALS over a 24-year period. Patients from the Piemonte and Valle d'Aosta registry for ALS (PARALS) were categorized into the first (1995–2002), second (2003–2010), or third (2011–2018) epoch based on their diagnosis date. Survival was defined as the time from diagnosis to death, tracheostomy, or censoring date. A Cox proportional hazard model was developed with diagnosis epoch as the primary variable of interest, adjusted for sex, site of onset, age at onset, diagnostic delay, forced vital capacity at diagnosis, Δbody mass index from onset to diagnosis, noninvasive mechanical ventilation use, gastrostomy use, and site of follow-up. A subset analysis comparing the 2007–2012 and 2013–2018 cohorts was conducted, incorporating riluzole prescription, genetics, and preslope category as additional covariates. A total of 3,134 patients were included, evenly distributed across the 3 epochs (990, 1,023, and 1,121, respectively). The median survival remained stable during the first and second epoch (18.6 months vs 18.3 months) but improved during the third epoch (20.1 months; p = 0.0041), with a hazard ratio (HR) of 0.76 (95% CI 0.67–0.87, p = 0.00003). In the subset analysis, the most recent epoch (2013–2018) showed a continued survival advantage (HR 0.77, 95% CI 0.65–0.90). Of interest, the survival benefit was only evident among intermediate progressors (HR 0.60, 95% CI 0.45–0.80). In the PARALS, ALS survival increased over time. In a subset analysis, the beneficial effect of the epoch was only evident among intermediate progressors. The improvement in multidisciplinary care provided by tertiary centers may be one possible explanation for this finding, although further dedicated studies are needed to confirm this hypothesis.
- 22 April 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (8) , e213467
Open AccessChanges to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995–2018)
The average survival of patients with amyotrophic lateral sclerosis (ALS) ranges from 2 to 5 years from symptom onset. However, it remains unclear whether this estimate has improved over time. The objective of this study was to analyze the survival trend of a large population-based cohort of patients with ALS over a 24-year period. Patients from the Piemonte and Valle d'Aosta registry for ALS (PARALS) were categorized into the first (1995–2002), second (2003–2010), or third (2011–2018) epoch based on their diagnosis date. Survival was defined as the time from diagnosis to death, tracheostomy, or censoring date. A Cox proportional hazard model was developed with diagnosis epoch as the primary variable of interest, adjusted for sex, site of onset, age at onset, diagnostic delay, forced vital capacity at diagnosis, Δbody mass index from onset to diagnosis, noninvasive mechanical ventilation use, gastrostomy use, and site of follow-up. A subset analysis comparing the 2007–2012 and 2013–2018 cohorts was conducted, incorporating riluzole prescription, genetics, and preslope category as additional covariates. A total of 3,134 patients were included, evenly distributed across the 3 epochs (990, 1,023, and 1,121, respectively). The median survival remained stable during the first and second epoch (18.6 months vs 18.3 months) but improved during the third epoch (20.1 months; p = 0.0041), with a hazard ratio (HR) of 0.76 (95% CI 0.67–0.87, p = 0.00003). In the subset analysis, the most recent epoch (2013–2018) showed a continued survival advantage (HR 0.77, 95% CI 0.65–0.90). Of interest, the survival benefit was only evident among intermediate progressors (HR 0.60, 95% CI 0.45–0.80). In the PARALS, ALS survival increased over time. In a subset analysis, the beneficial effect of the epoch was only evident among intermediate progressors. The improvement in multidisciplinary care provided by tertiary centers may be one possible explanation for this finding, although further dedicated studies are needed to confirm this hypothesis.
- 3 March 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (8) , 821-822
Another brick in our knowledge of ALS causes: a population-based study of residential clustering
Patients from the Piemonte and Valle d’Aosta registry for ALS (PARALS) diagnosed between 1995 and 2022 were considered.3 Residential histories were reconstructed from 1990 to symptom onset using municipal records, allowing us to identify buildings where two or more patients lived. Patients residing only in Valle d’Aosta were excluded. Familial cases and those with pathogenetic variants in SOD1, TARDBP, C9orf72 or FUS genes were also excluded to focus on common environmental exposures.
- 3 March 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (8) , 821-822
Another brick in our knowledge of ALS causes: a population-based study of residential clustering
Patients from the Piemonte and Valle d’Aosta registry for ALS (PARALS) diagnosed between 1995 and 2022 were considered.3 Residential histories were reconstructed from 1990 to symptom onset using municipal records, allowing us to identify buildings where two or more patients lived. Patients residing only in Valle d’Aosta were excluded. Familial cases and those with pathogenetic variants in SOD1, TARDBP, C9orf72 or FUS genes were also excluded to focus on common environmental exposures.
- Open Access
- 21 November 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (3) , 205-207
Navigating the presymptomatic frontier in genetic ALS and FTD
- 21 November 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (3) , 205-207
Open AccessNavigating the presymptomatic frontier in genetic ALS and FTD
- 9 October 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (5) , 1029
Reply to “Comprehensive Analysis of Sex Differences in Amyotrophic Lateral Sclerosis Prognosis and Disease Progression”
- 9 October 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (5) , 1029
Reply to “Comprehensive Analysis of Sex Differences in Amyotrophic Lateral Sclerosis Prognosis and Disease Progression”
- Open Access
- 6 September 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (1) , 100-102
IntermediateHTTCAG repeats worsen disease severity in amyotrophic lateral sclerosis
Recent research has indicated a connection between amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD), an inherited neurological condition caused by a trinucleotide CAG repeat expansion within exon 1 of the Huntingtin gene (HTT; MIM:613004).1 The same pathogenic CAG repeat expansions (40 or more CAG repeats) observed in patients with HD have been identified in patients with frontotemporal dementia (FTD)/ALS.1 Similarly, non-pathogenic intermediate-length CAG repeats in the ATXN2 gene are a well-established factor associated with increased ALS risk and faster disease progression.2 Given these observations, we investigated the impact of intermediate HTT alleles on survival in two cohorts of patients diagnosed with ALS.
- 6 September 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (1) , 100-102
Open AccessIntermediateHTTCAG repeats worsen disease severity in amyotrophic lateral sclerosis
Recent research has indicated a connection between amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD), an inherited neurological condition caused by a trinucleotide CAG repeat expansion within exon 1 of the Huntingtin gene (HTT; MIM:613004).1 The same pathogenic CAG repeat expansions (40 or more CAG repeats) observed in patients with HD have been identified in patients with frontotemporal dementia (FTD)/ALS.1 Similarly, non-pathogenic intermediate-length CAG repeats in the ATXN2 gene are a well-established factor associated with increased ALS risk and faster disease progression.2 Given these observations, we investigated the impact of intermediate HTT alleles on survival in two cohorts of patients diagnosed with ALS.
- Open Access
- 5 June 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 95 (8) , 722-729
Disentangling the relationship between social cognition, executive functions and behaviour changes in amyotrophic lateral sclerosis
Background Social cognition (SC) deficits are included in the amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTDS) revised diagnostic criteria. However, the impact of SC assessment on cognitive classification and the cognitive–behavioural correlates of SC remain unclear. This cross-sectional study aimed to assess the impact of SC assessment on ALS-FTDS categorisation and explore the relationship of SC with executive functions (EF) and behaviour changes in a cohort of ALS patients. Methods 121 patients and 56 healthy controls from the Turin ALS Centre underwent cognitive/behavioural testing, including the SC subdomains of facial emotion recognition, and cognitive and affective theory of mind (ToM). Results Patients performed significantly worse than controls in all SC explored domains, and 45% of patients exhibited a deficit in at least one SC test, dissociated from the presence of EF deficits. In 13% of cases, the SC deficit was isolated and subclinical. SC assessment contributed to the attribution of cognitive impairment in 10% of patients. Through a statistical clustering approach, we found that ToM only partially overlaps with EF while behaviour changes are associated with emotional disorders (anxiety and depression). Conclusions SC is overall independent of EF in ALS, with ToM only partially associated with specific EF measures, and behaviour changes associated with emotional disorders. The influence of SC on cognitive categorisation and the frequent identification of a subclinical SC impairment have implications in a clinical setting, considering the substantial impact of cognitive impairment on disease burden and therapeutic choices.
- 5 June 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 95 (8) , 722-729
Open AccessDisentangling the relationship between social cognition, executive functions and behaviour changes in amyotrophic lateral sclerosis
Background Social cognition (SC) deficits are included in the amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTDS) revised diagnostic criteria. However, the impact of SC assessment on cognitive classification and the cognitive–behavioural correlates of SC remain unclear. This cross-sectional study aimed to assess the impact of SC assessment on ALS-FTDS categorisation and explore the relationship of SC with executive functions (EF) and behaviour changes in a cohort of ALS patients. Methods 121 patients and 56 healthy controls from the Turin ALS Centre underwent cognitive/behavioural testing, including the SC subdomains of facial emotion recognition, and cognitive and affective theory of mind (ToM). Results Patients performed significantly worse than controls in all SC explored domains, and 45% of patients exhibited a deficit in at least one SC test, dissociated from the presence of EF deficits. In 13% of cases, the SC deficit was isolated and subclinical. SC assessment contributed to the attribution of cognitive impairment in 10% of patients. Through a statistical clustering approach, we found that ToM only partially overlaps with EF while behaviour changes are associated with emotional disorders (anxiety and depression). Conclusions SC is overall independent of EF in ALS, with ToM only partially associated with specific EF measures, and behaviour changes associated with emotional disorders. The influence of SC on cognitive categorisation and the frequent identification of a subclinical SC impairment have implications in a clinical setting, considering the substantial impact of cognitive impairment on disease burden and therapeutic choices.